Skip to main content
Clinical Trials/NCT03416023
NCT03416023TerminatedNot Applicable

Prospective Multicentre Open Clinical Study to Assess the Safety Performance and Durability of the TIES® Transcutaneous Titanium Implant in Patients Requiring a Permanent Ileostomy

Ostomycure AB4 sites in 2 countries28 target enrollmentStarted: October 30, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Sponsor
Enrollment
28
Locations
4
Primary Endpoint
Absence of Visible Leakage or Fecal Staining of Clothing at 24 Weeks

Study Overview

Brief Summary

Study to assess the safety, performance and durability of the TIES® transcutaneous titanium implant in patients requiring a permanent ileostomy.

Detailed Description

This is a multicentre, open-label, single-arm clinical study that will assess the safety, performance and durability of the TIES® transcutaneous titanium implant in patients requiring a permanent ileostomy (a surgical procedure that involves connecting the small intestine to the skin to create an opening).

The Transcutaneous Implant Evacuation System (TIES®) is a medical device designed to enable continence control for patients who would otherwise need to wear an ileostomy bag.

Eligible subjects will undergo a conventional ileostomy procedure under general anaesthesia and have the TIES® Port implanted. To date, the TIES® has been evaluated in 11 patients in 2 clinical studies. This study aims to collect more data that will assess performance, durability, safety and the impact that the TIES® has on a patient's quality of life.

The study will enroll 50 patients across Europe that require a permanent ileostomy, including patients with ulcerative colitis, familial adenomatous polyposis coli or other diseases such as Crohn´s disease.

Study subjects are expected to participate for approximately 1 year following surgical placement of the TIES® Port. Participation will involve a screening period, surgical implantation of the device (in-patient) and scheduled follow-up assessments out to 1 year post implant.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subject has ulcerative colitis, familial adenomatous polyposis coli or other diseases such as Crohn´s disease for whom a permanent ileostomy is indicated; or the subject has a medical need for an alternative to an existing conventional end-ileostomy, continent ileostomy or pelvic pouch; and
  • •Patient is a male ≥18 years of age or female ≥18 years of age (See exclusion criterion 4 regarding female with childbearing potential); and
  • •Signed written informed consent has been obtained prior to any study- related procedure.

Exclusion Criteria

  • •Concurrent gastrointestinal fistula, parastomal or incisional hernia, or a history of recurrent gastrointestinal fistula, recurrent parastomal hernia(s), and/or recurrent incisional hernia(s).
  • •Patients with undetermined colitis.
  • •An acute episode of Crohn´s disease occurring during the last three months before the operation
  • •Females who are of childbearing potential and do not wish to use birth control measures for the duration of the study
  • •Patients receiving immunosuppressives, oncologic treatment or anticoagulants.
  • •Any clinically significant, abnormal, baseline laboratory result which in the opinion of the surgeon, affects the patient's suitability for the study or puts the patient at risk if he/she undergoes surgery
  • •Severe illness which, in the opinion of the surgeon may put the patient at risk when participating in the study or may affect the patient's ability to complete the study visits
  • •Condition associated with the risk of poor protocol compliance, e.g. alcoholism and/or drug abuse, dementia, self-destructive personality disorder
  • •Subjects with BMI ≤ 17 kg/m2 or BMI ≥ 33 kg/m2
  • •Participate in other clinical studies that could interfere with the result in the ongoing study

Arms & Interventions

Single

Experimental

Intervention: TIES® (Transcutaneous Implant Evacuation System) (Device)

Outcomes

Primary Outcomes

Absence of Visible Leakage or Fecal Staining of Clothing at 24 Weeks

Time Frame: 24 weeks after implantation of the TIES® Port

Absence of visible leakage or fecal staining of clothing at 24 weeks after implantation of the TIES® Port.

Secondary Outcomes

  • Absence of Visible Leakage or Fecal Staining of Clothing at 16 Weeks(16 weeks)
  • Absence of Visible Leakage or Fecal Staining of Clothing 36 Weeks(36 weeks)
  • Subject's Preferences Regarding Daily Activities(52 weeks)
  • Absence of Visible Leakage or Fecal Staining of Clothing at 52 Weeks(52 weeks)
  • Proportion of Implanted Subjects Using the TIES Lid at 24 Weeks(24 weeks)
  • Proportion of Implanted Subjects Using the TIES Lid at 16 Weeks(16 weeks)
  • Proportion of Implanted Subjects Using the TIES Lid at 36 Weeks(36 weeks)
  • Proportion of Implanted Subjects Using the TIES Lid at 52 Weeks(52 weeks)
  • Subject's Preferences Regarding Maintaining Body Hygiene(52 weeks)
  • Subject's Preferences: Being Worried About Odor From Stoma(52 weeks)
  • Subject's Preferences: Being Worried About Leakage From Stoma(52 weeks)
  • Subject's Preferences: Recommending the TIES Solution(52 weeks)

Investigators

Sponsor
Ostomycure AB
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (4)

Loading locations...

Similar Trials